Open-Label Extension Study With REQUIP PR for Subjects From Study ROP111528
NCT01536574
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
295
Enrollment
INDUSTRY
Sponsor class
Conditions
Parkinson Disease
Interventions
DRUG:
Requip PR
Sponsor
GlaxoSmithKline